申请人:Cardone Michael H.
公开号:US20140221387A1
公开(公告)日:2014-08-07
The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
本发明涉及一种用于癌症治疗的组合物和方法,其中包括Formula I或Formula II的化合物。在某些方面,涵盖了B细胞淋巴瘤或其他造血系统癌症的治疗。在其他方面,本发明提供了治疗特定类型的造血系统癌症(如B细胞淋巴瘤)的方法,使用Formula I或Formula II的一个或多个化合物的组合。此外,还包括与26S蛋白酶体抑制剂等治疗药物类别(例如Bortezomib)的联合治疗。另一方面,本发明涉及使用Formula I或Formula II的化合物进行自身免疫治疗。在另一个方面,该发明涉及识别化合物的方法,例如BH3模拟类的化合物,这些化合物具有独特的体外特性,可以预测其对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的体内功效。